Theranexus Société Anonyme (ALTHX.PA)
EUR 0.64
(32.37%)
EUR 0.64
(32.37%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -7.38 Million EUR | -24.68% |
| 2022 | -5.92 Million EUR | 28.69% |
| 2021 | -8.67 Million EUR | -38.08% |
| 2020 | -5.72 Million EUR | 22.72% |
| 2019 | -7.22 Million EUR | -10.51% |
| 2018 | -6.93 Million EUR | -161.89% |
| 2017 | -2.69 Million EUR | -32.53% |
| 2016 | -2.03 Million EUR | -85.69% |
| 2015 | -1.1 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -178.17 Thousand EUR | 0.0% |
| 2023 Q4 | -3.55 Million EUR | 0.0% |
| 2023 FY | - EUR | -29.73% |
| 2023 Q2 | -3.99 Million EUR | 0.0% |
| 2022 Q4 | -2.9 Million EUR | 0.0% |
| 2022 FY | - EUR | 28.69% |
| 2022 Q2 | -3.43 Million EUR | 0.0% |
| 2021 Q2 | -4.35 Million EUR | 0.0% |
| 2021 FY | - EUR | -38.08% |
| 2021 Q4 | -3.99 Million EUR | 0.0% |
| 2020 Q4 | -2.56 Million EUR | 0.0% |
| 2020 FY | - EUR | 22.72% |
| 2020 Q2 | -3.45 Million EUR | 0.0% |
| 2019 FY | - EUR | -10.51% |
| 2019 Q4 | -3.67 Million EUR | 0.0% |
| 2019 Q2 | -4.11 Million EUR | 0.0% |
| 2018 FY | - EUR | -161.89% |
| 2018 Q4 | -4.05 Million EUR | 0.0% |
| 2018 Q2 | -2.98 Million EUR | 0.0% |
| 2017 FY | - EUR | -32.53% |
| 2017 Q4 | -1.83 Million EUR | 0.0% |
| 2017 Q1 | -672.63 Thousand EUR | 39.08% |
| 2017 Q2 | -856.56 Thousand EUR | -27.34% |
| 2016 Q2 | -932.06 Thousand EUR | -83.37% |
| 2016 FY | - EUR | -85.69% |
| 2016 Q1 | -508.3 Thousand EUR | 0.0% |
| 2016 Q4 | -1.1 Million EUR | 0.0% |
| 2015 Q2 | -273.31 Thousand EUR | 0.0% |
| 2015 Q3 | -273.31 Thousand EUR | 0.0% |
| 2015 Q4 | -508.3 Thousand EUR | -85.98% |
| 2015 FY | - EUR | 0.0% |
| 2015 Q1 | -273.31 Thousand EUR | 0.0% |
| 2014 Q4 | -273.31 Thousand EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.29 Million EUR | -124.536% |
| ABIVAX Société Anonyme | -133.2 Million EUR | 94.454% |
| Adocia SA | -22.73 Million EUR | 67.503% |
| Aelis Farma SA | -6.34 Million EUR | -16.389% |
| Biophytis S.A. | -13.8 Million EUR | 46.485% |
| Advicenne S.A. | -6.24 Million EUR | -18.309% |
| genOway Société anonyme | 6.35 Million EUR | 216.321% |
| IntegraGen SA | -52.5 Thousand EUR | -13970.112% |
| Medesis Pharma S.A. | -3.84 Million EUR | -92.131% |
| Neovacs S.A. | -8.44 Million EUR | 12.572% |
| NFL Biosciences SA | -4.04 Million EUR | -82.432% |
| Plant Advanced Technologies SA | 72.53 Thousand EUR | 10285.07% |
| Quantum Genomics Société Anonyme | -2.87 Million EUR | -157.083% |
| Sensorion SA | -22.31 Million EUR | 66.894% |
| TME Pharma N.V. | -5.07 Million EUR | -45.647% |
| Valbiotis SA | -6.95 Million EUR | -6.215% |
| TheraVet SA | -517.33 Thousand EUR | -1327.937% |
| Valerio Therapeutics Société anonyme | -18.91 Million EUR | 60.947% |
| argenx SE | -199.5 Million EUR | 96.297% |
| BioSenic S.A. | -6.79 Million EUR | -8.7% |
| Celyad Oncology SA | -7.76 Million EUR | 4.841% |
| DBV Technologies S.A. | -79.53 Million EUR | 90.711% |
| Galapagos NV | 51.03 Million EUR | 114.474% |
| Genfit S.A. | -28.05 Million EUR | 73.665% |
| GeNeuro SA | -14.31 Million EUR | 48.405% |
| Hyloris Pharmaceuticals SA | -14.98 Million EUR | 50.686% |
| Innate Pharma S.A. | -7.57 Million EUR | 2.517% |
| Inventiva S.A. | -101.84 Million EUR | 92.747% |
| MaaT Pharma SA | -19.74 Million EUR | 62.577% |
| MedinCell S.A. | -20.04 Million EUR | 63.149% |
| Nanobiotix S.A. | -34.01 Million EUR | 78.285% |
| Onward Medical N.V. | -35.23 Million EUR | 79.034% |
| Oryzon Genomics S.A. | -4.43 Million EUR | -66.628% |
| OSE Immunotherapeutics SA | -23.26 Million EUR | 68.249% |
| Oxurion NV | -16.72 Million EUR | 55.842% |
| Pharming Group N.V. | 4.98 Million EUR | 248.309% |
| Poxel S.A. | -12.17 Million EUR | 39.345% |
| GenSight Biologics S.A. | -21.73 Million EUR | 66.004% |
| Transgene SA | -27.02 Million EUR | 72.664% |
| Financière de Tubize SA | 184.57 Thousand EUR | 4102.379% |
| UCB SA | 1.26 Billion EUR | 100.582% |
| Valneva SE | -64.51 Million EUR | 88.55% |
| Vivoryon Therapeutics N.V. | -28.35 Million EUR | 73.946% |